ReShape Lifesciences® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software
June 29 2023 - 8:31AM
ReShape Lifesciences Inc. (Nasdaq:
RSLS), the premier physician-led weight loss and metabolic
health solutions company, today announced the signing of a
preferred partner agreement with Hive Medical (Hive). Hive’s
software suite leverages AI, machine-learning, SMS, and patient
self-service technology to increase patient volume.
“Our agreement with Hive is expected to
significantly improve our patient engagement strategy, which we
know, through our experience, is key to driving Lap-Band®
surgeries,” stated Paul F. Hickey, President and Chief Executive
Officer of ReShape Lifesciences. “We believe that incorporating the
Hive platform will enhance lead nurturing and the overall Lap-Band®
experience for patients, by allowing individuals to quickly and
easily navigate new patient intake hurdles and book an appointment
with a medical professional 24/7/365. This is evidenced in the data
we generated during our first quarter 2023 testing of the Hive
technology at select Lap-Band® accounts, where we also have co-op
marketing. In fact, integrating the Hive technology into our co-op
marketing campaign increased medical consultations by 107% for the
select accounts over the previous quarter. Based on these
outstanding results, we are excited to immediately roll-out the
Hive platform, on an exclusive basis, to additional accounts to
better address patient leads, with the intent of increasing
conversions and, ultimately, more Lap-Band® surgeries.”
About ReShape
Lifesciences®ReShape Lifesciences® is America’s premier
weight loss and metabolic health-solutions company, offering an
integrated portfolio of proven products and services that manage
and treat obesity and metabolic disease. The FDA-approved Lap-Band®
System provides minimally invasive, long-term treatment of obesity
and is an alternative to more invasive surgical stapling procedures
such as the gastric bypass or sleeve gastrectomy. ReShapeCare™ is a
virtual weight-management program that supports lifestyle changes
for all weight loss patients led by board-certified health coaches
to help them keep the weight off over time. ReShape Marketplace™ is
an online collection of quality wellness products curated for all
consumers to help them achieve their health goals. The
investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system
utilizes a proprietary vagus nerve block and stimulation technology
platform for the treatment of Type 2 diabetes and metabolic
disorders. The Obalon® balloon technology is a non-surgical,
swallowable, gas-filled intra-gastric balloon that is designed to
provide long-lasting weight loss. For more information, please
visit www.reshapelifesciences.com.
Forward-Looking Safe Harbor
Statement This press release may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Actual results could differ materially from
those discussed due to known and unknown risks, uncertainties, and
other factors. These forward-looking statements generally can be
identified by the use of words such as "expect," "plan,"
"anticipate," "could," "may," "intend," "will," "continue,"
"future," other words of similar meaning and the use of future
dates. Forward-looking statements in this press release include the
statements that we expect our agreement with Hive to significantly
improve our patient engagement strategy and lead nurturing. These
and additional risks and uncertainties are described more fully in
the company's filings with the Securities and Exchange Commission,
including those factors identified as "risk factors" in our most
recent Annual Report on Form 10-K and subsequent Quarterly Reports
on Form 10-Q. We are providing this information as of the date of
this press release and do not undertake any obligation to update
any forward-looking statements contained in this document as a
result of new information, future events or otherwise, except as
required by law.
CONTACTSReShape Lifesciences Investor
Contact:Thomas StankovichChief Financial
Officer949-276-6042ir@ReShapeLifesci.com
Investor Relations Contact:Rx
Communications GroupMichael
Miller(917)-633-6086mmiller@rxir.com
ReShape Lifesciences (NASDAQ:RSLS)
Historical Stock Chart
From Apr 2024 to May 2024
ReShape Lifesciences (NASDAQ:RSLS)
Historical Stock Chart
From May 2023 to May 2024